Cargando…
Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation
The MDM2 oncogene has been suggested as a molecular target for treating human cancers, including breast cancer. Most MDM2 inhibitors under development are targeting the MDM2-p53 binding, and have little or no effects on cancers without functional p53, such as advanced breast cancer. The present stud...
Autores principales: | Qin, Jiang-Jiang, Wang, Wei, Voruganti, Sukesh, Wang, Hui, Zhang, Wei-Dong, Zhang, Ruiwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413606/ https://www.ncbi.nlm.nih.gov/pubmed/25739118 |
Ejemplares similares
-
Oral nano-delivery of anticancer ginsenoside 25-OCH(3)-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action
por: Voruganti, Sukesh, et al.
Publicado: (2015) -
Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA
por: Qin, Jiang-Jiang, et al.
Publicado: (2015) -
Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy
por: Qin, Jiang-Jiang, et al.
Publicado: (2016) -
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
por: Qin, Jiang-Jiang, et al.
Publicado: (2016) -
Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects
por: Kon, Ning, et al.
Publicado: (2018)